Kura Oncology (NASDAQ:KURA) Upgraded at Zacks Research

Zacks Research upgraded shares of Kura Oncology (NASDAQ:KURA) from a strong sell rating to a hold rating in a research note released on Thursday,Zacks.com reports.

Several other equities analysts have also weighed in on the company. HC Wainwright reissued a “buy” rating and set a $40.00 price objective on shares of Kura Oncology in a report on Tuesday, January 13th. Wall Street Zen upgraded Kura Oncology from a “sell” rating to a “hold” rating in a research note on Sunday, February 22nd. Leerink Partners set a $20.00 price objective on Kura Oncology and gave the company an “outperform” rating in a research note on Tuesday, January 13th. UBS Group upped their price objective on shares of Kura Oncology from $14.00 to $16.00 and gave the company a “buy” rating in a report on Friday, November 14th. Finally, Barclays reiterated an “overweight” rating and set a $28.00 target price (up from $11.00) on shares of Kura Oncology in a research report on Monday, November 24th. Nine analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $28.00.

Kura Oncology Stock Performance

NASDAQ KURA opened at $8.73 on Thursday. The company has a market capitalization of $759.68 million, a PE ratio of -3.52 and a beta of 0.23. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.12 and a current ratio of 5.12. Kura Oncology has a 52-week low of $5.41 and a 52-week high of $12.49. The company has a 50-day simple moving average of $8.99 and a 200 day simple moving average of $9.35.

Insider Activity at Kura Oncology

In related news, insider Mollie Leoni sold 8,180 shares of the company’s stock in a transaction that occurred on Tuesday, January 27th. The shares were sold at an average price of $8.46, for a total transaction of $69,202.80. Following the sale, the insider owned 267,274 shares of the company’s stock, valued at approximately $2,261,138.04. This represents a 2.97% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Thomas James Doyle sold 7,142 shares of the firm’s stock in a transaction on Tuesday, January 27th. The shares were sold at an average price of $8.46, for a total transaction of $60,421.32. Following the completion of the transaction, the senior vice president directly owned 145,167 shares of the company’s stock, valued at approximately $1,228,112.82. The trade was a 4.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 59,794 shares of company stock valued at $537,176 in the last quarter. 6.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of KURA. IFP Advisors Inc raised its stake in Kura Oncology by 115.3% in the fourth quarter. IFP Advisors Inc now owns 2,398 shares of the company’s stock valued at $25,000 after purchasing an additional 1,284 shares in the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of Kura Oncology by 392.8% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 3,854 shares of the company’s stock worth $34,000 after buying an additional 3,072 shares during the last quarter. Allworth Financial LP lifted its holdings in shares of Kura Oncology by 59.9% during the 4th quarter. Allworth Financial LP now owns 4,146 shares of the company’s stock worth $43,000 after acquiring an additional 1,553 shares during the last quarter. PNC Financial Services Group Inc. grew its position in Kura Oncology by 127.2% in the third quarter. PNC Financial Services Group Inc. now owns 6,732 shares of the company’s stock worth $60,000 after acquiring an additional 3,769 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its position in Kura Oncology by 471.3% in the second quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company’s stock worth $70,000 after acquiring an additional 9,958 shares in the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.